Literature DB >> 16805689

Human periodontal fibroblast response to enamel matrix derivative, amelogenin, and platelet-derived growth factor-BB.

Chol H Chong1, David L Carnes, Alan J Moritz, Thomas Oates, Ok Hee Ryu, James Simmer, David L Cochran.   

Abstract

BACKGROUND: The ideal goal of clinical therapy in periodontal defects is regeneration of all lost structures. For regeneration to occur, cell proliferation, migration, and extracellular matrix synthesis are prerequisites. Attempts at regeneration of periodontal defects by guided tissue regeneration using bone grafts and membranes have not always yielded predictable results. Recently, attempts at engineering the defects using various materials have shown promising results. Two such approaches have been used to regenerate periodontal defects, one using extracellular matrix such as enamel matrix proteins and the other using growth factors. However, to our knowledge, no study has looked at combining these two approaches to achieve potentially even greater regeneration.
METHODS: Primary human periodontal ligament (PDL) fibroblasts were explanted, and alkaline phosphatase (ALK PHOS) activity was determined. Phenotypically different cell lines were incubated for 1, 3, 6, and 10 days in 0.2% fetal bovine serum (FBS) media containing different concentrations of either enamel matrix derivative (EMD), amelogenin, platelet-derived growth factor-BB (PDGF-BB), EMD+PDGF-BB, or amelogenin+PDGF-BB. A culture of 0.2% FBS alone served as a negative control, and a culture of 10% FBS served as a positive control. Cell proliferation was measured using a Coulter counter to determine the cell number. The effects on a wound-fill model were evaluated by scraping a 3-mm wide cell-free zone in PDL monolayers across the diameter of the tissue-culture plate and determining PDL cell migration into the cell-free zone using computer assisted histomorphometry.
RESULTS: Compared to the control, only EMD+PDGF-BB significantly increased PDL cell proliferation in an ALK PHOS (-) cell line (P<0.001), and EMD alone, EMD+PDGF-BB, and amelogenin+PDGF-BB significantly increased PDL cell proliferation in an ALK PHOS (+) cell line (P<0.001) with EMD+PDGF-BB showing a trend for greater proliferation than either PDGF or EMD alone. Individually, EMD and amelogenin had no significant effect on PDL cell proliferation. In the wound-fill experiment, all factors and their combinations except amelogenin significantly enhanced cell migration compared to the control (P<0.05) at the wound edge. In addition, EMD+PDGF-BB had additive effects on the ALK PHOS (-) cell line at the wound edge. At the center of the wound, neither EMD nor amelogenin had a significant wound-fill effect. However, the combination of EMD+PDGF-BB additively increased wound fill for both ALK PHOS (+) and ALK PHOS (-) cells.
CONCLUSIONS: The combination of EMD and PDGF-BB produces greater proliferative and wound-fill effects on PDL cells than each by themselves. If these combined effects can be translated clinically, one may see greater regeneration in periodontal defects with this combination. However, amelogenin does not have significant effects on PDL cell proliferation or migration by itself. This may suggest that either another enamel matrix component in EMD may be responsible for some of its clinical effects, or that amelogenin alone may not trigger the regenerative potential of periodontal tissues and that it requires a combined interaction with other enamel matrix components of EMD to direct the regenerative process.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16805689     DOI: 10.1902/jop.2006.050147

Source DB:  PubMed          Journal:  J Periodontol        ISSN: 0022-3492            Impact factor:   6.993


  8 in total

1.  Effect of PDGF-BB combined with EDTA gel on adhesion and proliferation to the root surface.

Authors:  Mahmoud Helmy Belal; Hisashi Watanabe; Shizuko Ichinose; Isao Ishikawa
Journal:  Odontology       Date:  2012-01-17       Impact factor: 2.634

2.  A proof of concept gene-activated titanium surface for oral implantology applications.

Authors:  Noah Z Laird; Walla I Malkawi; Jaidev L Chakka; Timothy M Acri; Satheesh Elangovan; Aliasger K Salem
Journal:  J Tissue Eng Regen Med       Date:  2020-03-04       Impact factor: 3.963

3.  Human periodontal ligament fibroblasts stimulated by nanocrystalline hydroxyapatite paste or enamel matrix derivative. An in vitro assessment of PDL attachment, migration, and proliferation.

Authors:  Adrian Kasaj; Brita Willershausen; Rüdiger Junker; Stefan-Ioan Stratul; Mirko Schmidt
Journal:  Clin Oral Investig       Date:  2011-06-07       Impact factor: 3.573

4.  Enamel matrix proteins exhibit growth factor activity: A review of evidence at the cellular and molecular levels.

Authors:  Marzena Wyganowska-Świątkowska; Paulina Urbaniak; Michał Marek Nohawica; Małgorzata Kotwicka; Jerzy Jankun
Journal:  Exp Ther Med       Date:  2015-04-07       Impact factor: 2.447

5.  Role of cathepsin S In periodontal wound healing-an in vitro study on human PDL cells.

Authors:  Svenja Memmert; Marjan Nokhbehsaim; Anna Damanaki; Andressa V B Nogueira; Alexandra K Papadopoulou; Christina Piperi; Efthimia K Basdra; Birgit Rath-Deschner; Werner Götz; Joni A Cirelli; Andreas Jäger; James Deschner
Journal:  BMC Oral Health       Date:  2018-04-05       Impact factor: 2.757

6.  Development and application of a 3D periodontal in vitro model for the evaluation of fibrillar biomaterials.

Authors:  Franziska Koch; Nina Meyer; Silvio Valdec; Ronald E Jung; Stephanie H Mathes
Journal:  BMC Oral Health       Date:  2020-05-19       Impact factor: 2.757

7.  Bone formation with disruption of the lamina dura in the mandibular third molar.

Authors:  Minoru Yamaoka; Masahide Ishizuka; Masahiro Takahashi; Takashi Uematsu; Kiyofumi Furusawa
Journal:  Clin Cosmet Investig Dent       Date:  2010-01-05

Review 8.  Amelogenin, an extracellular matrix protein, in the treatment of venous leg ulcers and other hard-to-heal wounds: experimental and clinical evidence.

Authors:  Marco Romanelli; Valentina Dini; Peter Vowden; Magnus S Agren
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.